TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20932130

Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy (2,940 nm, 60 mJ/pulse, 2 Hz, 20 s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser therapy (1,064 nm, 100 mJ/pulse, 15 Hz, 100 s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diode laser therapy (808 nm, 100 mW, 20s)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not irradiated)
Number of subjects: 24
Study: 18379555

Group type: EXPERIMENTAL
Intervention: High volume peritoneal dialysis (HVPD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Daily hemodialysis (DHD)
Number of subjects: 120
Study: 12271300

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times per week for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle cream applied to the other side of the body
Number of subjects: 22
Study: 9649912

Group type: EXPERIMENTAL
Intervention: Enalapril 10-40 mg o.d. after 3 and 12 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide monotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hypertensive patients during exercise
Number of subjects: 25
Study: 7530029

Group type: EXPERIMENTAL
Intervention: bovine heparin 300 u. kg‐1 (standard)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: heparin 300 u. kg‐1 followed by a continuous infusion of 10,000 u. kg‐1 until the end of CPB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: heparin 600 u. kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: heparin 600 u. kg‐1 in addition to high‐dose aprotinin 2 million iu before CPB, 500,000 iu h‐1 until the end of operation and 2 million iu added to the prime
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline solution (control)
Number of subjects: 60
Study: 2586435

Group type: EXPERIMENTAL
Intervention: Oral OK-432
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Intravenous OK-432
Number of subjects: 1011
Study: 781905

Group type: EXPERIMENTAL
Intervention: Busulphan (mean dosage of 464 mg over 301 days)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 28146393

Group type: EXPERIMENTAL
Intervention: MPFL reconstruction in addition to TTT and LR
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (lateral release and TTT)
Number of subjects: 34
Study: 25030898

Group type: EXPERIMENTAL
Intervention: Combined rTMS and LLLT
Number of subjects: 30

Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 30
Study: 23556337

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-G carriers of ABCB1 G2677T/A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SLCO1B1*17 carriers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Female SLCO1B1 521TT subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 12
Study: 21813728

Group type: EXPERIMENTAL
Intervention: Hormone therapy cessation for 1 month or 2 months before the next screening mammogram
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Continuation of hormone therapy
Number of subjects: 1168
Study: 19918152

Group type: EXPERIMENTAL
Intervention: Social cognitive theory-based structured hip fracture prevention website (TSW) with learning modules and a moderated discussion board for 2 weeks
Number of subjects: 90
Study: 16444660

Group type: EXPERIMENTAL
Intervention: 600 mg dose of Melissa officinalis and Valeriana officinalis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1800 mg dose of Melissa officinalis and Valeriana officinalis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg, 1200 mg, and 1800 mg doses of Melissa officinalis and Valeriana officinalis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg and 1200 mg doses of Melissa officinalis and Valeriana officinalis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14992980

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 978

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Galantamine (8, 16, or 24 mg/day)
Number of subjects: 978
Study: 11434897

Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 2702
Study: 9374712

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 40
Study: 8498732

Group type: EXPERIMENTAL
Intervention: Bronchodilator treatment
Number of subjects: 58
Study: 30289174

Group type: EXPERIMENTAL
Intervention: Interactive decision tool (iCanDecide)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group (static website)
Number of subjects: 537
Study: 27695851

Group type: EXPERIMENTAL
Intervention: ParentCorps-enhanced prekindergarten programs
Number of subjects: 1050
Study: 24630869

Group type: EXPERIMENTAL
Intervention: Vi-rEPA conjugate vaccine
Number of subjects: 0
Study: 22506886

Group type: EXPERIMENTAL
Intervention: Interprofessional simulation program
Number of subjects: 84
Study: 20420639

Group type: EXPERIMENTAL
Intervention: TAC/MMF/DAC
Number of subjects: 196

Group type: COMPARATOR
Intervention: TAC/MMF/STR
Number of subjects: 196
Study: 18824016

Group type: EXPERIMENTAL
Intervention: Motion-defined contours in peripheral vision with drifting dots and static dot patterns.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniform dark area substituted for static dots.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two fields of dots moving in opposite directions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying the velocity of the more eccentric region.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminability of contours in diverging and converging patterns.
Number of subjects: 0
Study: 16490583

Group type: EXPERIMENTAL
Intervention: Oral clindamycin 300 mg BID
Number of subjects: 774

Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanic acid 1 g BID
Number of subjects: 774
Study: 14672477

Group type: EXPERIMENTAL
Intervention: Spanish version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ)
Number of subjects: 26

Group type: COMPARATOR
Intervention: English version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire (PISQ)
Number of subjects: 26
Study: 10623706

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m²/d for 5 days every 28 days)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) (250 mg/m²/d for 5 days every 21 days)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 305

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 305
Study: 9180443

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 39
Study: 8250314

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flumazenil 3 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flumazenil 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 32
Study: 3814226

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ketanserin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg clonidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 7
Study: 30972696

Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.125-2.25 mg/kg)
Number of subjects: 45
Study: 29986688

Group type: EXPERIMENTAL
Intervention: Child Health Intervention for Development Outcomes (CHIDO) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ministry of Health standard care
Number of subjects: 30
Study: 27022112

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 561

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 561
Study: 25233931

Group type: EXPERIMENTAL
Intervention: Nicotine metabolism by cytochrome P450 2A6‐catalyzed C‐oxidation
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: UDP‐glucuronosyl transferase 2B10 (UGT2B10)‐catalyzed N‐glucuronidation
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: UGT2B10 genotype variants (Asp67Tyr, rs61750900 and rs116294140)
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: UGT2B10 variant allele carriers
Number of subjects: 1839
Study: 22292153

Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with nonocclusal loading (Group A)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with occlusal loading (Group B)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Delayed loading with single-stage surgery (Group C)
Number of subjects: 117
Study: 20816146

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P) 250 mg weekly injections
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 81
Study: 17885721

Group type: EXPERIMENTAL
Intervention: Pre-germinated brown rice
Number of subjects: 41

Group type: COMPARATOR
Intervention: White rice (control)
Number of subjects: 41
Study: 16253149

Group type: EXPERIMENTAL
Intervention: Rib-cage compression before endotracheal suctioning
Number of subjects: 31

Group type: COMPARATOR
Intervention: Endotracheal suctioning without rib-cage compression
Number of subjects: 31
Study: 12374435

Group type: EXPERIMENTAL
Intervention: Instrumental aggression (facilitated by personal rewards)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive aggression (facilitated by situational provocation)
Number of subjects: 0
Study: 10440559

Group type: EXPERIMENTAL
Intervention: New method for detecting selection bias based on response data only.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline comparisons across treatment groups.
Number of subjects: 0
Study: 7751077

Group type: EXPERIMENTAL
Intervention: Braked jumps using the Plyometric Power System (PPS) with braking mechanism set at 75% of body weight during the downward phase.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-braked jumps (control condition).
Number of subjects: 20
Study: 1983724

Group type: EXPERIMENTAL
Intervention: Alprazolam, 1.5 mg/day
Number of subjects: 100
Study: 400194

Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI) and Chemotherapy (CVP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chemotherapy (CVP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of TBI and CVP
Number of subjects: 21
Study: 30576268

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone (DP) or a DP-containing regimen
Number of subjects: 8820
Study: 28124802

Group type: EXPERIMENTAL
Intervention: Frequent consumption of Caspian white fish marinated in essential oil of Perilla frutescens (EOPF), 434 g each week or four meals per week.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Frequent consumption of Caspian white fish without EOPF, 434 g each week or four meals per week.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Common diet (control group).
Number of subjects: 180
Study: 26229455

Group type: EXPERIMENTAL
Intervention: Minimal alcohol intake (<1 drink/month)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol intake (1-60 drinks/month)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>60 drinks/month)
Number of subjects: 1082
Study: 21200007

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID (D110)
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID (D150)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1270
Study: 19620877

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 25
Study: 17065182

Group type: EXPERIMENTAL
Intervention: Intensive intervention at a heart failure clinic by a clinician and a cardiovascular nurse, including 9 scheduled patient contacts over 1 year, comprehensive education, treatment optimisation, and self-care advice.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intensive intervention at a heart failure clinic
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (outpatient visits by individual cardiologists following European Society of Cardiology guidelines)
Number of subjects: 240
Study: 12868997

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 10832622

Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation in pure mitral stenosis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Echocardiographic evaluation in normal persons
Number of subjects: 44
Study: 9094063

Group type: EXPERIMENTAL
Intervention: MMEPs recorded at 1, 3, 30, and 90 days after stroke, measuring amplitudes and latencies/central motor conduction times (CMCTs) from hypothenar, biceps brachialis, gastrocnemius, and quadriceps.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MMEPs values included in prognosis calculations.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased blood pressure.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased heart rate and hyperglycemia.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variables: infarction size on second CT, age, and first day CMCT-S1.
Number of subjects: 50
Study: 8245671

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g and tinidatsole 500 mg
Number of subjects: 628

Group type: COMPARATOR
Intervention: Aminoglycoside (netilmycin 150 mg or tobramycin 80 mg) with tinidatsole
Number of subjects: 628
Study: 3533818

Group type: EXPERIMENTAL
Intervention: Immunoglobulin treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 22
Study: 31056923

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM)
Number of subjects: 31
Study: 27862873

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 948

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 948
Study: 26290082

Group type: EXPERIMENTAL
Intervention: Reoperation group (119 patients)
Number of subjects: 810

Group type: COMPARATOR
Intervention: No reoperation group (691 patients)
Number of subjects: 810
Study: 23443753

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 145

Group type: COMPARATOR
Intervention: Hypothetical comparator
Number of subjects: 145
Study: 21067735

Group type: EXPERIMENTAL
Intervention: Third Eye colonoscopy (TEC)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 448
Study: 19210135

Group type: EXPERIMENTAL
Intervention: NER uncoated 2 x 500 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NER coated 1 x 1000 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NER coated 2 x 500 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NER uncoated 1 x 1000 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 25
Study: 16735333

Group type: EXPERIMENTAL
Intervention: Contact at one month
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control (usual treatment)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Contact at three months
Number of subjects: 605
Study: 15548759

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (alpha‐tocopherol 100 mg/day, beta‐carotene 6 mg/day, vitamin C 100 mg/day, selenium 50 microg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 11546715

Group type: EXPERIMENTAL
Intervention: Clonidine (1 microg x kg(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 9760346

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dextrose placebo
Number of subjects: 6
Study: 8091168

Group type: EXPERIMENTAL
Intervention: OME/AMOX (oral OME 40 mg bid and AMOX solute 750 mg tid for 10 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: OME (20 mg per day for 20 days)
Number of subjects: 52
Study: 2968363

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 36
Study: 30013785

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (375–3000 mg/day)
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Standard therapy (non-iron-based phosphate binders)
Number of subjects: 1359
Study: 27129956

Group type: EXPERIMENTAL
Intervention: Two-session risk-reduction counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized standard care (control)
Number of subjects: 0
Study: 25789814

Group type: EXPERIMENTAL
Intervention: Full fan pattern at maximum smile
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Lower fan pattern
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Full fan and lower fan patterns
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: CFL pattern distribution
Number of subjects: 1392
Study: 24101048

Group type: EXPERIMENTAL
Intervention: Dose-intensive temozolomide
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (control)
Number of subjects: 182
Study: 21816628

Group type: EXPERIMENTAL
Intervention: Glenohumeral (GH) steroid injection
Number of subjects: 71

Group type: COMPARATOR
Intervention: Subacromial (SA) steroid injection
Number of subjects: 71
Study: 19386684

Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combined sedation (midazolam and hydrocodone)
Number of subjects: 200
Study: 16690379

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude chiropractic adjustments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonintervention group (control)
Number of subjects: 10
Study: 15560690

Group type: EXPERIMENTAL
Intervention: Garlic enteric coated tablets for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets for 3 months
Number of subjects: 100
Study: 11422249

Group type: EXPERIMENTAL
Intervention: amoxycillin‐clavulanate (13.3 mg/kg 3 times daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: cefuroxime axetil (15 mg/kg twice daily)
Number of subjects: 28
Study: 9430448

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID, 5 mg, orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP, 0.3 or 0.6 mM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH (10-8 M)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH with ID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 12
Study: 8018953

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment for less than 2 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment for 2 weeks or more
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment after 2 weeks
Number of subjects: 36
Study: 3144446

Group type: EXPERIMENTAL
Intervention: Fluoride tablet programme (daily administration)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Control group (no fluoride tablets)
Number of subjects: 529
Study: 29233783

Group type: EXPERIMENTAL
Intervention: 30-minute tDCS combined with 50mg/day of sertraline
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 20-minute tDCS combined with 50mg/day of sertraline
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 69
Study: 26242834

Group type: EXPERIMENTAL
Intervention: External stent applied to SVGs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonstented SVGs (control)
Number of subjects: 29
Study: 24202240

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus whole breast irradiation (WBI)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI) alone
Number of subjects: 1428
Study: 16271726

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg twice daily (BID)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 12825868

Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10633478

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 ug/kg, i.m.) on night 2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo on night 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery night (night 3)
Number of subjects: 12
Study: 7755525

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 71
Study: 2076303

Group type: EXPERIMENTAL
Intervention: Eight-hour educational program including interactive discussion groups, influential peers, and self-formulated contracts.
Number of subjects: 0